---
layout: default
title: Biotin
parent: 僅模型預測 (L5)
nav_order: 29
evidence_level: L5
indication_count: 2
---

# Biotin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# BIOTIN: Drug Repurposing Evaluation Report

## One-Sentence Summary

Biotin (Vitamin B7) is a water-soluble B-complex vitamin identified in DrugBank (DB00121), with no approved pharmaceutical indications currently registered in Taiwan. The TxGNN model has **not generated any predicted new indications** for this compound, and there is **no clinical trial or literature evidence** available in this evidence pack to support repurposing at this time.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | None registered (no Taiwan marketing authorization) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No model predictions and no supporting studies |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

**No TxGNN prediction was generated for Biotin.** Without a predicted indication, a mechanistic rationale analysis cannot be performed.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological knowledge, Biotin (Vitamin B7) is an essential cofactor for carboxylase enzymes involved in fatty acid synthesis, gluconeogenesis, and amino acid catabolism. It functions as a coenzyme for acetyl-CoA carboxylase, pyruvate carboxylase, and other biotin-dependent carboxylases. However, these properties alone have not led the TxGNN model to identify any novel therapeutic indications.

The absence of a prediction may reflect that Biotin's primary role is nutritional rather than pharmacotherapeutic, or that the knowledge graph does not contain sufficient disease–target edges to generate a high-confidence repurposing signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

*(The `predicted_indications` array is empty; no indication-specific trial search was performed.)*

---

## Literature Evidence

Currently no related literature available.

*(The `predicted_indications` array is empty; no indication-specific literature search was performed.)*

---

## Taiwan Market Information

Biotin has **no marketing authorizations** in Taiwan. There are no registered pharmaceutical products containing Biotin as an active ingredient in the TFDA database.

---

## Safety Considerations

> Please refer to the package insert for safety information.

No key warnings, contraindications, or drug–drug interactions were retrieved for Biotin in this evidence pack. The TFDA package insert query returned 1 result, but no structured safety data was extracted. Further review of the original source document is recommended.

---

## Data Gaps Identified

The following critical data gaps were flagged during evidence collection:

| Gap ID | Category | Item | Severity | Impact | Remediation |
|--------|----------|------|----------|--------|-------------|
| DG001 | Drug Level | TFDA Package Insert Warnings/Contraindications | **Blocking** | Cannot proceed to S1 safety screening | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Affects mechanistic relevance analysis | Query DrugBank API |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model did not generate any predicted indications for Biotin. Combined with the absence of Taiwan marketing authorizations, the lack of MOA data, and blocking safety data gaps, there is no actionable repurposing signal to evaluate at this time.

**To proceed, the following is needed:**
- Resolve **DG001** (Blocking): Retrieve and parse TFDA package insert warnings and contraindications
- Resolve **DG002** (High): Obtain detailed mechanism of action data from DrugBank API
- Re-run TxGNN prediction pipeline to confirm whether the empty prediction set is due to insufficient graph connectivity or a genuine absence of signal
- If Biotin is primarily classified as a nutritional supplement rather than a therapeutic drug, consider whether it falls within the scope of this repurposing programme
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

